InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,718.57
(
0.28%
)
US TECH 100
19,312.80
(
0.08%
)
Dow Jones
42,124.65
(
0.15%
)
Brent Oil
73.46
(
-0.38%
)
Bitcoin
62,885.56
(
-0.70%
)
Post# of 23979
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

murocman

Send PM Follow Ignore
Followers 12
Posts 924
Boards Moderated 0
Alias Born 08/01/2006

murocman

Re: None

Thursday, 01/12/2017 8:58:24 PM

Thursday, January 12, 2017 8:58:24 PM

Post# of 23979
TENX - Phase III data for LEVO-CTS Trial due this month. Drug already approved outside of North America (Simdax) and has been used in over 1 million patients so success of trial is de-risked.

$50M market cap

28M shares outstanding, 17M Float

Almost 40% institutional ownership with likes of Sabby, Broadfin and Baker Brothers.

Stock just over $2 with 52-wk range of $1.21-2.94.

Could be a mover on positive data.

GLTA,

Murocman
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up